FDA OKs Nivolumab in Metastatic CRC Subtype - Medscape

Medscape

FDA OKs Nivolumab in Metastatic CRC Subtype Medscape These defects are found most commonly in colorectal, endometrial, and gastrointestinal cancers but also less commonly appear in cancers arising in the breast, prostate, bladder, thyroid gland, and other places, the agency noted. The FDA also said that ... Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer ...Business Wire (press release) all 15 news articles »

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vtOnZL
via IFTTT